

Anti-TNFSF11/RANKL/CD254 Antibody (Denosumab)

Introduction

Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective in inhibiting giant cell tumor of bone (GCTB). Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, densely cellular tumor stromal cells.

Product parameters

Alternative Names	AMG-162
Target Accession	O14788
Target	TNFSF11 / RANKL / CD254
CAS number	615258-40-7
Molecular Weight	145.16 kDa
Host	СНО
Reactivity	Human, Mouse, Rat
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.













APExBIO Technology www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com